PhRMA Comments to USPTO on Terminal Disclaimer Practice to Obviate Nonstatutory Double Patenting

Graphic of a fountain pen writing on a piece of paper

The Pharmaceutical Research and Manufacturers of America (PhRMA) is pleased to submit these comments in response to the United States Patent and Trademark Office’s (USPTO) Notice of Proposed Rulemaking on Terminal Disclaimer Practice to Obviate Nonstatutory Double Patenting (May 10, 2024).

Graphic of a fountain pen writing on a piece of paper

This website uses cookies and other tracking technologies to optimize performance, preferences, usage, and statistics. By clicking “Accept All”, you consent to store on your device the cookies and other tracking technologies that require consent. You can tailor or change your preferences by clicking “Manage My Cookies”. You can check our privacy policy for more information.